Esophageal cancer is the 8th most common cancer and 6th leading cause of cancer-related deaths in the world. The overall prognosis of esophageal cancer is poor with a 5-year survival that ranges from 15 to 25%. However, improved patient outcomes have been reported when esophageal cancer is diagnosed in its early stages. Cancers of the esophagus are primarily categorized into two subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Although the incidence of esophageal adenocarcinoma has increased rapidly, esophageal squamous cell carcinoma remains the predominant form of esophageal cancer worldwide and accounts for 80% of all cases. The accumulation of genetic alterations has a pivotal role during malignant progression of normal esophageal squamous mucosa to esophageal squamous cell carcinoma. Studies implicate a number of well-known tumor suppressor genes and oncogenes, such as TP53, CDKN2A, PIK3CA, RB1 and genes within the receptor tyrosine kinase/mitogen-activated protein kinase pathways.
To better understand the relationship between the mutation of esophageal cancer-related genes and the molecular biology mechanism of esophageal cancer, CD Genomics utilizes targeted NGS sequencing technology and offers a comprehensive library of esophageal cancer panel. If necessary, you can choose genes that fit your requirements.
We provide customized bioinformatics analysis including:
CD Genomics provides the accurate and cost-effective esophageal cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for esophageal cancer panel sequencing is outlined below.
For more information about the esophageal cancer panel or need other amplification requirements, please contact us.